Consumer Healthcare eCommerce Professionals Gear up for their First Global ePharmacy Summit
Online sales of OTCs, prescription drugs and parapharmacy products in beauty, food and baby-care categories have been surging in the last years, with COVID-19 bringing extra waves of consumer demand. With this new eCommerce segment on the rise, more than 1,000 representatives of Retailers & Manufacturers of Consumer Healthcare products will be coming together on the 4th, 5th & 6th of November in the world’s first ePharmacy Summit. The three-day virtual event is organized by Convert Group, the leading Market Intelligence organization of Consumer Healthcare products & FMCGs sold online. You can read more about the event at epharmacysummit.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201004005052/en/
(Graphic: Business Wire)
Top professionals from 20 countries that are leading ePharma strategies in their local and international markets will be sharing their experiences, discussing trends and presenting best practices with a global consumer healthcare audience.
Confirmed Speakers include:
- Martin Moore | eCommerce Director EMEA, J&J [UK]
- David Maso | Head of Europe, Zur Rose Group [Germany]
- Prasanna Pitale | SVP Global Consumer Healthcare, IQVIA [UK]
- Guillaume Gauthier | Healthcare Industry Manager, Google [Germany]
- Anne de Witte | International Business Unit Development & Project Director, Pierre Fabre [France]
- Nicholas Hall | President, Nicholas Hall [UK]
- Rasha Rady | COO U& cofounder, chefaa [Egypt]
- Georgios Kaperonis | ex Head of Analytics Tesco / founder Decisively [Greece]
- Mikhail Chulin | ePharmacy Business Development Manager, ePharmacy, Yandex [Russia]
- Elena Chailazopoulou | Director of Product Innovation & Deputy CEO, Convert Group [Greece]
and 15 more speakers from Korea to Mexico City.
The Summit's chair, Panayotis Gezerlis, founder & CEO of Convert Group, stated: "An industry advances when leaders share knowledge, experience and data. At Convert Group we are excited to host the first global ePharmacy Summit and we are preparing to welcome top Consumer Healthcare professionals with an interest in eCommerce from around the world."
Attendees will also have access to an unparalleled online networking experience, real-time translation into 109 languages and will be able to visit virtual booths of industry changemakers. Tickets are sold per person or per organization.
For more information, visit epharmacysummit.com and browse through the agenda, book your tickets, or contact the organizers for sponsorship opportunities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201004005052/en/
Contact information
Labrini Bena
Jr Communications & PR
Email: info@epharmacysummit.com
Tel: +44 203 808 4800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom